毕得医药(688073.SH)：股东舟山欣曦、宁波兰旦及其一致行动人拟合计减持不超2.86%股份

Core Viewpoint - Bid Pharma (688073.SH) announced a share reduction plan by its shareholders due to personal liquidity needs, which may impact the stock price and market perception of the company [1] Shareholder Reduction Plan - Shareholder Zhoushan Xinxie plans to reduce up to 908,829 shares through block trading, representing 1.00% of the total share capital [1] - Shareholder Ningbo Landan also intends to reduce up to 908,829 shares through block trading, equivalent to 1.00% of the total share capital [1] - Shareholder Wu Bo aims to reduce up to 785,804 shares through centralized bidding, accounting for 0.86% of the total share capital [1] - The reduction prices will be determined based on the market prices at the time of execution [1]